Breast Cancer Now Annual Report 2016/17
Every month breast cancer takes the lives of nearly 1,000 people. These are real people, with real lives, who we need to give more precious time to live.
Our Annual Report and Accounts 2016/17 show that our work has never been more important. Together with the brightest scientific minds, the best fundraisers and the most determined campaigners, partners and patient advocates we will stop breast cancer and save lives.
Our accounts from previous years
* This report represents an amalgamation of results from Breast Cancer Campaign and Breakthrough Breast Cancer up to 31 March 2015, plus the results of the merged charity, Breast Cancer Now, from 1 April to 31 July 2015.
Legacy charity accounts
Download the Annual Report and Accounts for Breast Cancer Campaign and Breakthrough Breast Cancer, the two charities that merged in June 2015 to form Breast Cancer Now.
Breast Cancer Campaign annual reports
Breakthrough Breast Cancer annual reports
Pharmaceutical donations 2013 - 2017
Download the figures (pdf)
The Breast Cancer Now Catalyst Programme
The Breast Cancer Now Catalyst Programme, is an initiative which aims to bring together Europe’s leading breast cancer researchers and the world’s leading pharmaceutical companies to pool resources and stop women dying from breast cancer by 2050. The first collaborator signed up to the Catalyst Programme is the biopharmaceutical company Pfizer. Pfizer has committed $15m USD (around £10m) over three years, which opens an exciting opportunity for breast cancer research.
The programme aims to enable Europe’s leading researchers to design independently selected research programmes, using companies’ existing breast cancer drugs or molecules that they’re still working on in their laboratories. We aim to speed up the translation of research into new more effective targeted treatments and therapies for breast cancer patients.
Please contact our Supporter Engagement team with any questions by emailing firstname.lastname@example.org or calling 0333 20 70 300.